Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.
The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.
Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。